Improving direct pharmacist counseling rates for oral oncolytic medications at an outpatient oncology clinic

Background: Because of the increasing prevalence of the use of oncolytic orally to patients with malignancies, implementation and monitoring strategies to improve patient safety has become a necessity. Our focus is on the American Society of Oncology Quality Oncology Practice Initiative (QOPI) clinical standards of care, standards of 2.3, and the need for counseling patients before the first administration of oral oncolytic therapy.

Objective: To assess the implementation of strategies for improving the workflow to determine their effect on the number of patients reached for pharmacist counseling prior to the first dose of oral oncolytic drugs.
Methods: In this study a quasi-experimental quality improvement, we formed a multidisciplinary group to develop and implement processes workflow improvements. This process is focused on the redistribution of workflow and application of new technology in EPIC Beacon.

Results: A total of 86 patients were identified as eligible for counseling (38 pre-intervention, post-intervention 48). There was a statistically significant increase in the number of eligible patients counseled in the post-intervention period compared to the pre-intervention period (100% vs 86.84%; 95% CI = -0.212, -0.205; P = 0.017). No significant difference was observed in the number of in-person advising patients or advising patients before the first dose.

Conclusion: Our intervention shows the level of 100% of the advice in the post-intervention period. Further work needs to be done to increase the number of patients we reach before they take their first dose of the drug, as well as the number of patients we can advice face to face.

The relationship between in-line filtration and Type I hypersensitivity reactions in pediatric oncology patients who receive intravenous etoposide

The purpose of this study was to describe hypersensitivity reactions with and without the use of in-line filter for intravenous etoposide therapy in pediatric oncology patients. This is a retrospective review of all patients who were treated in the Division of Oncology / Hematology / Bone Marrow Transplant at Children’s Hospital of British Columbia with intravenous etoposide between December 1, 2013 and February 1, 2018. hypersensitivity and anaphylactic reactions associated with infusion of etoposide compared over time, including 12 months earlier, 27 months for use, and for 12 months after the cessation of in-line filtration.

There were 192 patients (average age of 6.0 (IQR 2.8 to 13.0) years were treated with etoposide and etoposide infusion 486 including 137 (28%) previously, 261 (54%) for and 88 (18%) after use filter in-line at our center. twenty-six of 486 (5%) and 13/486 (3%) of infusions resulted in type I hypersensitivity reactions and anaphylaxis, respectively.

There were 2/137 (1%), 36 / 261 (14%.) and 1/88 (1%) infusion reactions before, during and after an in-line filter, each infusion reaction during the period-line filter is higher than during the pre-filter (Z = 3.978; p <0.001) and post-filter (Z = 3.335 ;. p <0.001) in the period of research data show that the use of in-line filtration may be associated with an increased frequency of hypersensitivity reaction to etoposide in pediatric cancer patients.

 Improving direct pharmacist counseling rates for oral oncolytic medications at an outpatient oncology clinic
Improving direct pharmacist counseling rates for oral oncolytic medications at an outpatient oncology clinic

Why Racial Justice Matters in Radiation Oncology

The recent events have reaffirmed that racism is a pervasive disease disrupt the United States and the infiltration of the fabric of this nation. As health care professionals dedicated to understanding and reduce disease, many radiation oncologists have failed to recognize how structural racism affect the health and well-being of patients we aim to serve. Literature is full of descriptive statistics which show a higher incidence and mortality experienced by the Black population’s health conditions ranging from infant mortality to infectious diseases, including the coronavirus disease in 2019 (COVID-19).

The recognition that the roots of health inequalities experienced by Black people in this country based on racism is essential to move the nation and advanced the field of radiation oncology. With this lens, a brief overview of the structural and institutional racism shape the discussion about what radiation oncologists and their representative organizations can do to cope with this disaster. As a member of the technology, we often use the power of data to improve human health and disease challenge with optimism that approach multidisciplinary effort can result in healing. Some principles to reduce the old problem of the Black marginalization in the field has been recommended by ATIP (Recognition, transparency, intentionality, and representation) and lead (Learn, Engage, Advocate, Advocate, Support) approach.

However, additional introspection recommended. Just like individuals, practices and organizations rallied to determine how best to address the problems associated with the 19th COVID pandemic, studied the same spirit should be applied to the issue of racism to combat this evil and often deadly disease.

Nurse-led oral and maxillofacial oncology clinic: a review

The oral and maxillofacial (OMFS) head “nurse-led” and neck (H & N) clinics have been introduced and developed over the last decade, and we are now close to the point that this effort could potentially be applied nationally. This paper is a systematic review of the proposed clinical models OMFS H & N nurse-led.

VEGF-KDR, Peptide Aptamer, FITC labelled

AP-337-F 1 mg Ask for price

VEGF mimotope (avastin binding peptide) M074_F02

200-851-P 100 ug
EUR 196.8

VEGF mimotope (avastin binding peptide) M074_D12

200-852-P 100 ug
EUR 196.8

VEGF receptor Flt-1 (F56), Peptide Aptamer, unlabeled

AP-334-U 5 mg Ask for price

VEGF-stimulated Human Umbilical Vein Endothelial Cell, Peptide Aptamer, unlabeled

AP-338-U 5 mg Ask for price

VEGF-stimulated human umbilical vein endothelial cells, Peptide Aptamer, unlabeled

AP-339-U 5 mg Ask for price

VEGF-stimulated Human Umbilical Vein Endothelial Cell, Peptide Aptamer, Biotinylated

AP-338-B 1 mg Ask for price

VEGF receptor Flt-1 (F56), Peptide Aptamer, Biotinylated

AP-334-B 1 mg Ask for price

VEGF-stimulated human umbilical vein endothelial cells, Peptide Aptamer, Biotinylated

AP-339-B 1 mg Ask for price

VEGF-stimulated Human Umbilical Vein Endothelial Cell, Peptide Aptamer, FITC labelled

AP-338-F 1 mg Ask for price

VEGF receptor Flt-1 (F56), Peptide Aptamer, FITC labelled

AP-334-F 1 mg Ask for price

VEGF receptor KDR/Flk-1 (K237), Peptide Aptamer, unlabeled

AP-336-U 5 mg Ask for price

VEGF-stimulated human umbilical vein endothelial cells, Peptide Aptamer, FITC labelled

AP-339-F 1 mg Ask for price

VEGF receptor KDR/Flk-1 (K237), Peptide Aptamer, Biotinylated

AP-336-B 1 mg Ask for price

VEGF receptor KDR and Flt-1 (v107), Peptide Aptamer, unlabeled

AP-335-U 5 mg Ask for price

VEGF receptor KDR/Flk-1 (K237), Peptide Aptamer, FITC labelled

AP-336-F 1 mg Ask for price

VEGF receptor KDR and Flt-1 (v107), Peptide Aptamer, Biotinylated

AP-335-B 1 mg Ask for price

VEGF receptor KDR and Flt-1 (v107), Peptide Aptamer, FITC labelled

AP-335-F 1 mg Ask for price

EG-VEGF Blocking Peptide

20-abx064278
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

VEGFA Peptide

43-168P 0.1 mg
EUR 405.6

VEGFR1 Peptide (OVA)

20-abx165607
  • EUR 693.60
  • EUR 309.60
  • EUR 2064.00
  • EUR 828.00
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human FLT-1/VEGFR-1 Control/blocking peptide #1

FLT11-P 100 ug
EUR 196.8

Human FLT-4/VEGFR-3 control/blocking peptide #2

FLT42-P 100 ug
EUR 196.8

VEGFD Blocking Peptide

20-abx062622
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

VEGFB Blocking Peptide

20-abx063414
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

VEGFA Blocking Peptide

20-abx061882
  • EUR 309.60
  • EUR 460.80
  • 1 mg
  • 5 mg

VEGFC Blocking Peptide

20-abx061931
  • EUR 309.60
  • EUR 460.80
  • 1 mg
  • 5 mg

VEGFD Blocking Peptide

AF5192-BP 1mg
EUR 234

VEGFB Blocking Peptide

AF5250-BP 1mg
EUR 234

VEGFB Blocking Peptide

AF7019-BP 1mg
EUR 234

VEGFA Blocking Peptide

33R-8432 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of VEGFA antibody, catalog no. 70R-10216

VEGFB Blocking Peptide

33R-3169 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of VEGFB antibody, catalog no. 70R-9647

VEGFB Blocking Peptide

33R-7386 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of VEGFB antibody, catalog no. 70R-9646

VEGFC Blocking Peptide

DF7011-BP 1mg
EUR 234

VEGFA Blocking Peptide

DF7470-BP 1mg
EUR 234

VEGFB Blocking Peptide

DF6855-BP 1mg
EUR 234

VEGFR1 Blocking Peptide

AF7748-BP 1mg
EUR 234

VEGFR3 Blocking Peptide

AF4201-BP 1mg
EUR 234

VEGFR1 Blocking Peptide

AF6204-BP 1mg
EUR 234

VEGFR2 Blocking Peptide

AF6279-BP 1mg
EUR 234

VEGFR2 Blocking Peptide

AF6281-BP 1mg
EUR 234

VEGFR3 Blocking Peptide

DF2689-BP 1mg
EUR 234

VEGFR1 Blocking Peptide

20-abx161622
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

VEGFR1 Blocking Peptide

20-abx161858
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

VEGFR2 Blocking Peptide

20-abx161912
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

VEGFR2 Blocking Peptide

20-abx161913
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

VEGFR2 Blocking Peptide

20-abx161915
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

VEGFR2 (pY951) Blocking Peptide

20-abx161914
  • EUR 376.80
  • EUR 610.80
  • 1 mg
  • 5 mg

VEGFR1 (pY1213) Blocking Peptide

20-abx062629
  • EUR 376.80
  • EUR 610.80
  • 1 mg
  • 5 mg

VEGFR2 (pY1214) Blocking Peptide

20-abx061614
  • EUR 360.00
  • EUR 594.00
  • 1 mg
  • 5 mg

VEGFR2 (pY1175) Blocking Peptide

20-abx162540
  • EUR 376.80
  • EUR 610.80
  • 1 mg
  • 5 mg

Human Peptide YY (PYY) Peptide

20-abx068451
  • EUR 693.60
  • EUR 309.60
  • EUR 2013.60
  • EUR 811.20
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

VEGFR-KDR/Flk-1 Antagonist Peptide

H-5896.0001 1.0mg
EUR 691.2
Description: Sum Formula: C77H99N23O18S; CAS# [492444-99-2] net

VEGFR-KDR/Flk-1 Antagonist Peptide

H-5896.0005 5.0mg
EUR 2648.4
Description: Sum Formula: C77H99N23O18S; CAS# [492444-99-2] net

AP2A1 Peptide

43-204P 0.1 mg
EUR 405.6

Human Antigen Peptide Transporter 2 (TAP2) Peptide

20-abx650296
  • EUR 678.00
  • EUR 309.60
  • EUR 1980.00
  • EUR 794.40
  • EUR 493.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Antigen Peptide Transporter 1 (TAP1) Peptide

20-abx650298
  • EUR 777.60
  • EUR 326.40
  • EUR 2397.60
  • EUR 927.60
  • EUR 560.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Cathelicidin Antimicrobial Peptide (CAMP) Peptide

20-abx065799
  • EUR 927.60
  • EUR 360.00
  • EUR 2932.80
  • EUR 1111.20
  • EUR 661.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Connecting Peptide (C-Peptide) Peptide

abx670072-05mg 0.5 mg
EUR 678

Human Peptide YY (PYY) Peptide (OVA)

20-abx651848
  • EUR 693.60
  • EUR 309.60
  • EUR 2064.00
  • EUR 828.00
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Anti cyclic cirtullinated peptide ELISA kit

E01C0708-192T 192 tests
EUR 1524
Description: A competitive ELISA for quantitative measurement of Human Anti cyclic cirtullinated peptide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Human Anti cyclic cirtullinated peptide ELISA kit

E01C0708-48 1 plate of 48 wells
EUR 624
Description: A competitive ELISA for quantitative measurement of Human Anti cyclic cirtullinated peptide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Human Anti cyclic cirtullinated peptide ELISA kit

E01C0708-96 1 plate of 96 wells
EUR 822
Description: A competitive ELISA for quantitative measurement of Human Anti cyclic cirtullinated peptide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Anti-Flt1 Peptide

20-abx265801
  • EUR 393.60
  • EUR 594.00
  • EUR 326.40
  • 10 mg
  • 25 mg
  • 5 mg

Anti-Flt1 Peptide

5-00708 4 x 5mg Ask for price

Apaf1 Peptide

2013P 0.05 mg
EUR 197.7
Description: (NT) Apaf1 peptide

Apaf1 Peptide

2015P 0.05 mg
EUR 197.7
Description: (CT) Apaf1 peptide

Phospho-VEGF Receptor 2 (Tyr1175) Blocking Peptide

AF4426-BP 1mg
EUR 234

Anti-Kentsin Peptide

20-abx265748
  • EUR 393.60
  • EUR 594.00
  • EUR 326.40
  • 10 mg
  • 25 mg
  • 5 mg

Human Caspase peptide-17(Caspase peptide-17)

QY-E05408 96T
EUR 433.2

Human Liver Expressed Antimicrobial Peptide 2 (LEAP2) Peptide

20-abx067816
  • EUR 1028.40
  • EUR 376.80
  • EUR 3300.00
  • EUR 1228.80
  • EUR 710.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Brain Natriuretic Peptide (BNP) Peptide

20-abx065599
  • EUR 878.40
  • EUR 343.20
  • EUR 2766.00
  • EUR 1062.00
  • EUR 627.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Brain natriuretic peptide (BNP) Peptide

abx670010-01mg 0.1 mg
EUR 360

Human Osteogenic Growth Peptide (OGP) Peptide

20-abx652290
  • EUR 661.20
  • EUR 292.80
  • EUR 1914.00
  • EUR 777.60
  • EUR 493.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Atrial Natriuretic Peptide (ANP) Peptide

20-abx652084
  • EUR 693.60
  • EUR 309.60
  • EUR 2064.00
  • EUR 828.00
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

AP2A1 Blocking Peptide

33R-8194 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of AP2A1 antibody, catalog no. 70R-9953

AP2A2 Blocking Peptide

33R-8256 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of AP2A2 antibody, catalog no. 70R-9954

AP2A2 Blocking Peptide

DF7319-BP 1mg
EUR 234

Human Vasoactive Intestinal Peptide (VIP) Peptide

20-abx069654
  • EUR 794.40
  • EUR 326.40
  • EUR 2448.00
  • EUR 944.40
  • EUR 577.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Vasoactive Intestinal Peptide (VIP) Peptide

20-abx652275
  • EUR 693.60
  • EUR 309.60
  • EUR 2013.60
  • EUR 811.20
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human VEGF 121 Antibody

32562-05111 150 ug
EUR 313.2

Human VEGF 165 Antibody

32563-05111 150 ug
EUR 313.2

Human C- Peptide, connecting peptide ELISA Kit

CELI-66099h 96 Tests
EUR 988.8

Human Glucagon-Like Peptide 2 (GLP2) Peptide

abx670345-1mg 1 mg
EUR 427.2

anti- peptide YY antibody

FNab06310 100µg
EUR 702
Description: Antibody raised against peptide YY

Human anti cyclic citrullinated peptide antibody ELISA kit

E01A2058-192T 192 tests
EUR 1524
Description: A competitive ELISA for quantitative measurement of Human anti cyclic citrullinated peptide antibody in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Human anti cyclic citrullinated peptide antibody ELISA kit

E01A2058-48 1 plate of 48 wells
EUR 624
Description: A competitive ELISA for quantitative measurement of Human anti cyclic citrullinated peptide antibody in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Human anti cyclic citrullinated peptide antibody ELISA kit

E01A2058-96 1 plate of 96 wells
EUR 822
Description: A competitive ELISA for quantitative measurement of Human anti cyclic citrullinated peptide antibody in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Human anti-cyclic citrullinated peptide,CCP ELISA Kit

201-12-0564 96 tests
EUR 528
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Human anti-cyclic citrullinated peptide,CCP ELISA Kit

CN-04354H1 96T
EUR 556.8

Human anti-cyclic citrullinated peptide,CCP ELISA Kit

CN-04354H2 48T
EUR 375.6

Human anti-cyclic citrullinated peptide(CCP)ELISA Kit

GA-E0580HM-48T 48T
EUR 346.8

Human anti-cyclic citrullinated peptide(CCP)ELISA Kit

GA-E0580HM-96T 96T
EUR 559.2

Human anti-cyclic citrullinated peptide(CCP)ELISA Kit

QY-E02624 96T
EUR 433.2

Human anti-cyclic citrullinated peptide,CCP ELISA Kit

YLA2279HU-48T 48T
EUR 435

Human anti-cyclic citrullinated peptide,CCP ELISA Kit

YLA2279HU-96T 96T
EUR 562.5

human VEGF Antibody

E13-a001 100μg
EUR 458.4

Human cathelicidin antimicrobial peptide (CAMP) Control/blocking peptide

AB-23041-P 100ug
EUR 196.8

Human C-Type Natriuretic Peptide (NPPC) Peptide

20-abx066173
  • EUR 744.00
  • EUR 326.40
  • EUR 2230.80
  • EUR 878.40
  • EUR 543.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Brain Natriuretic Peptide (BNP) Peptide (BSA)

20-abx651076
  • EUR 393.60
  • EUR 243.60
  • EUR 1011.60
  • EUR 477.60
  • EUR 326.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Brain Natriuretic Peptide (BNP) Peptide (OVA)

20-abx651077
  • EUR 693.60
  • EUR 309.60
  • EUR 2064.00
  • EUR 828.00
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Brain Natriuretic Peptide (BNP) Peptide (OVA)

20-abx651078
  • EUR 309.60
  • EUR 226.80
  • EUR 678.00
  • EUR 343.20
  • EUR 276.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Brain Natriuretic Peptide (BNP) Peptide (OVA)

20-abx651079
  • EUR 326.40
  • EUR 226.80
  • EUR 727.20
  • EUR 360.00
  • EUR 276.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Brain Natriuretic Peptide (BNP) Peptide (OVA)

20-abx651080
  • EUR 309.60
  • EUR 226.80
  • EUR 678.00
  • EUR 343.20
  • EUR 276.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Gastrin Releasing Peptide (GRP) Peptide (BSA)

20-abx651228
  • EUR 493.20
  • EUR 260.40
  • EUR 1262.40
  • EUR 560.40
  • EUR 360.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Peptide YY, Human

5-01749 4 x 1mg Ask for price

Peptide YY (human)

H-9180.0500 0.5mg
EUR 400.8
Description: Sum Formula: C194H295N55O57; CAS# [118997-30-1] net

Peptide YY (human)

H-9180.1000 1.0mg
EUR 618
Description: Sum Formula: C194H295N55O57; CAS# [118997-30-1] net

Human Delta Sleep-Inducing Peptide (dSIP) Peptide

20-abx066303
  • EUR 794.40
  • EUR 326.40
  • EUR 2431.20
  • EUR 944.40
  • EUR 577.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Amyloid Beta Peptide 1-40 (Ab1-40) Peptide

20-abx652283
  • EUR 376.80
  • EUR 243.60
  • EUR 927.60
  • EUR 410.40
  • EUR 309.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Amyloid Beta Peptide 1-40 (Ab1-40) Peptide

abx670346-1mg 1 mg
EUR 627.6

Human Glutaminyl Peptide Cyclotransferase (QPCT) Peptide

20-abx168154
  • EUR 794.40
  • EUR 326.40
  • EUR 2448.00
  • EUR 944.40
  • EUR 577.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Peptide YY (PYY) (Human) antibody

Y072 50 ul
EUR 512.4
Description: The Peptide YY (PYY) (Human) antibody is available in Europe and for worldwide shipping via Gentaur.

Human Calcitonin Gene Related Peptide (CGRP) Peptide

20-abx065658
  • EUR 710.40
  • EUR 309.60
  • EUR 2131.20
  • EUR 844.80
  • EUR 526.80
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Glucagon Like Peptide 2 (GLP2) Peptide (OVA)

20-abx651238
  • EUR 543.60
  • EUR 276.00
  • EUR 1462.80
  • EUR 627.60
  • EUR 393.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Glucagon Like Peptide 2 (GLP2) Peptide (OVA)

20-abx165542
  • EUR 693.60
  • EUR 309.60
  • EUR 2064.00
  • EUR 828.00
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Natriuretic Peptide Precursor B (NPPB) Peptide

20-abx652101
  • EUR 878.40
  • EUR 343.20
  • EUR 2766.00
  • EUR 1062.00
  • EUR 627.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Pro-Gastrin Releasing Peptide (ProGRP) Peptide

20-abx168685
  • EUR 744.00
  • EUR 326.40
  • EUR 2264.40
  • EUR 895.20
  • EUR 543.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Trypsinogen Activation Peptide (TAP) Peptide (BSA)

20-abx651098
  • EUR 309.60
  • EUR 226.80
  • EUR 644.40
  • EUR 326.40
  • EUR 260.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Trypsinogen Activation Peptide (TAP) Peptide (OVA)

20-abx651099
  • EUR 309.60
  • EUR 226.80
  • EUR 644.40
  • EUR 326.40
  • EUR 260.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Gastrin Releasing Peptide Receptor (GRPR) Peptide

20-abx650009
  • EUR 811.20
  • EUR 343.20
  • EUR 2498.40
  • EUR 961.20
  • EUR 577.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human anti-cyclic citrullinated peptide antibody,Anti-CCP AB ELISA Kit

YLA3924HU-48T 48T
EUR 435

Human anti-cyclic citrullinated peptide antibody,Anti-CCP AB ELISA Kit

YLA3924HU-96T 96T
EUR 562.5

Human C-Type Natriuretic Peptide (NPPC) Peptide (OVA)

20-abx651832
  • EUR 678.00
  • EUR 309.60
  • EUR 1980.00
  • EUR 794.40
  • EUR 493.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human C-Peptide (CP) Peptide (OVA)

20-abx651801
  • EUR 693.60
  • EUR 309.60
  • EUR 2064.00
  • EUR 828.00
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Amyloid Beta Peptide 1-40 (Ab1-40) Peptide (BSA)

20-abx651143
  • EUR 376.80
  • EUR 243.60
  • EUR 927.60
  • EUR 410.40
  • EUR 309.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Amyloid Beta Peptide 1-40 (Ab1-40) Peptide (OVA)

20-abx651144
  • EUR 577.20
  • EUR 292.80
  • EUR 1646.40
  • EUR 678.00
  • EUR 410.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Amyloid Beta Peptide 1-40 (Ab1-40) Peptide (KLH)

20-abx651145
  • EUR 410.40
  • EUR 260.40
  • EUR 1078.80
  • EUR 493.20
  • EUR 326.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Amyloid Beta Peptide 1-42 (Ab1-42) Peptide (BSA)

20-abx651173
  • EUR 376.80
  • EUR 243.60
  • EUR 978.00
  • EUR 427.20
  • EUR 309.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Amyloid Beta Peptide 1-42 (Ab1-42) Peptide (OVA)

20-abx651174
  • EUR 594.00
  • EUR 292.80
  • EUR 1696.80
  • EUR 693.60
  • EUR 427.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Amyloid Beta Peptide 1-42 (Ab1-42) Peptide (KLH)

20-abx651842
  • EUR 693.60
  • EUR 309.60
  • EUR 2064.00
  • EUR 828.00
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Amyloid Beta Peptide 1-42 (Ab1-42) Peptide (OVA)

20-abx165506
  • EUR 744.00
  • EUR 326.40
  • EUR 2230.80
  • EUR 878.40
  • EUR 543.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Amyloid Beta Peptide 1-40 (Ab1-40) Peptide (OVA)

20-abx165634
  • EUR 727.20
  • EUR 309.60
  • EUR 2180.40
  • EUR 861.60
  • EUR 526.80
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

The literature on the topic is limited: only eight papers were eligible were identified and reviewed. The rated focuses on four domains: requirements / needs, actual costs, patient safety and outcomes, and education and training. Most of the advantages / benefits of the proposed clinic had previously been discussed. The current review has revealed that the published evidence available on the clinical concept OMFS H & N nurse led indicate that they may not be necessary.

Related Posts

Leave a Reply

Your email address will not be published.